Market News AIOpen the app

Wedbush lowered its price target for Larimar Therapeutics from $11 to $9 but still thinks it will do well.

OpinionRead the original at marketscreener.com
Neutral

Wedbush lowered its target but kept its Outperform rating. The mixed analyst signals report no new change in Larimar's drug progress or finances.

LRMR · Larimar Therapeutics, Inc.

AI read · Neutral

The AI's read

That is a change in one firm's estimate, not a new report about trial results, cash, or regulatory progress. Its unchanged rating points the other way, so neither signal clearly outweighs the other.

Get alerts for LRMR

Follow Larimar Therapeutics, Inc. (LRMR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LRMR
Free on the App Store and Google Play, or on the web.